Endonovo Therapeutics (Endonovo Therapeutics) 5-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics 5-Year EBITDA Growth Rate?

Endonovo Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was -66.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Endonovo Therapeutics was 80.10% per year. The lowest was -66.80% per year. And the median was 67.20% per year.

Competitive Comparison of Endonovo Therapeutics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Endonovo Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's 5-Year EBITDA Growth Rate falls into.

Endonovo Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Endonovo Therapeutics (OTCPK:ENDV) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Endonovo Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367